Search Results

BioMidwest

European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations

New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott’s CardioMEMS™ HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor.

May 24, 2023

·

5 min read

BioMidwest

JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

Daxor Corporation announces a new research letter in the Journal of the American College of Cardiology – Heart Failure validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

July 12, 2023

·

3 min read

FDA

Abbott’s CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the company’s CardioMEMS™ HF System to support the care of more people living with heart failure.

February 21, 2022

·

5 min read

BioMidwest

GUIDE-HF Study Data Show Abbott’s CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure

Abbott (NYSE: ABT) today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS™ HF System in people living with NYHA Class II, III and IV heart failure.

August 27, 2021

·

6 min read

New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

March 23, 2023

·

3 min read

Drug Development

Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor

Abbott announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System.

March 29, 2018

·

3 min read

Business

CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27.

June 25, 2024

·

2 min read

Business

GT Medical Technologies, Inc. Appoints Two Industry Medical Device Veterans to Key Leadership Positions

GT Medical Technologies, Inc. today announced two significant additions to its leadership team: Tom Moore as Chief Commercial Officer and Sandeep Yadav as Chief Financial Officer.

June 20, 2024

·

2 min read

BioMidwest

CVRx announces availability of additional data supporting long-term benefits of Barostim

CVRx, Inc., a commercial-stage medical device company, announced the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure.

April 15, 2024

·

3 min read

Business

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Robert Mashal, M.D. to its Board of Directors.

January 8, 2024

·

2 min read